China Children's Leukemia Group (CCLG)-APL2021 study on pediatric acute promyelocytic leukemia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052966

Enrollment

Unknown

Registered

2021-11-06

Start date

2021-11-08

Completion date

Unknown

Last updated

2022-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

childhood acute promyelocytic leukemia

Interventions

non-high risk group:ATRA+Arsenic

high risk group:ATRA+Arsenic+antharcycline

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Patients newly diagnosed APL with PML-RARapositive and/or t(15;17)(q22;q21) ; 2. Patients younger than 18 years old; 3. Patients with normal heart function; 4. Patients who have signed the Informed Consent Form.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to retinoic acid or arsenic agents involved in this program; 2. Participate in other clinical investigators during the same period.

Design outcomes

Primary

Measure	Time frame
overall survival rate;Event-free survival rate;	—

Secondary

Measure	Time frame
Hematologic complete remission;Molecular complete remission;early mortality rate;cumulative disease rate of relapse;	—

Countries

China

Contacts

Public ContactZheng Huyong

Beijing Children's Hospital, Capital Medical University

zhenghuyong@bch.com.cn+86 10 59617621

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026